ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,602.20
0.43%
S&P ASX All Technology
2,982.90
0.47%
Brent Oil
83.995
0.54%
US Dollar vs AUD
1.53069
-0.02%
Bitcoin
57,406.70
-1.42%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vaxcyte Inc (PCVX)

  7. Vaxcyte Inc (PCVX) News

PCVX Vaxcyte Inc

63.71
3.16 (5.22%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Vaxcyte Inc PCVX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
3.16 5.22% 63.71 08:09:01
Open Price Low Price High Price Close Price Previous Close
60.76 60.21 64.24 63.71 60.55
more quote information »

Recent News

Date Time Source Heading
03/4/202407:05GLOBEVaxcyte to Present at the 23rd Annual Needham Virtual..
05/3/202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202413:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202413:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:30GLOBEVaxcyte Completes Enrollment of Phase 2 Study Evaluating..
02/3/202408:02EDGAR2Form 144 - Report of proposed sale of securities
02/3/202408:00EDGAR2Form 144 - Report of proposed sale of securities
28/2/202408:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/2/202408:02EDGAR2Form 8-K - Current report
28/2/202408:01GLOBEVaxcyte Reports Fourth Quarter and Full Year 2023 Financial..
21/2/202408:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202408:05GLOBEVaxcyte to Report Fourth Quarter and Full Year 2023..
06/2/202409:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202409:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202410:39GLOBEVaxcyte Announces Closing of $862.5 Million Public Offering..
02/2/202408:07EDGAR2Form 144 - Report of proposed sale of securities
02/2/202408:06EDGAR2Form 144 - Report of proposed sale of securities
02/2/202408:05GLOBEVaxcyte to Present at the Guggenheim Healthcare Talks | 6th..
01/2/202409:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/2/202409:19EDGAR2Form 8-K - Current report
31/1/202415:37GLOBEVaxcyte Announces Pricing of $750 Million Public Offering
31/1/202408:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/1/202408:01GLOBEVaxcyte Announces Commencement of Proposed Public Offering..
30/1/202400:30GLOBEVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating..
17/1/202408:01GLOBEVaxcyte Appoints Whitney Jones as Chief People Officer
05/1/202408:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202408:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202408:01GLOBEVaxcyte Provides Clinical and Regulatory Progress Update on..
03/1/202408:04EDGAR2Form 144 - Report of proposed sale of securities
03/1/202408:03EDGAR2Form 144 - Report of proposed sale of securities
12/12/202308:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202308:15EDGAR2Form 144 - Report of proposed sale of securities
06/12/202308:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202310:35GLOBEVAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in..
02/12/202308:12EDGAR2Form 144 - Report of proposed sale of securities
30/11/202308:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202308:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/11/202300:32EDGAR2Form 8-K - Current report
29/11/202300:30GLOBEVaxcyte Appoints Jacks Lee to Board of Directors
28/11/202308:05EDGAR2Form 8-K - Current report
28/11/202308:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
10/11/202300:30GLOBEVaxcyte Doses First Participants in Phase 1/2 Clinical Study..
07/11/202308:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202308:07EDGAR2Form 8-K - Current report
07/11/202308:03GLOBEVaxcyte Reports Third Quarter 2023 Financial Results and..
04/11/202307:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202307:07EDGAR2Form 144 - Report of proposed sale of securities
01/11/202307:05GLOBEVaxcyte to Present at Upcoming Investor Conferences
20/10/202300:29DJNVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine..
19/10/202323:30GLOBEVaxcyte Announces FDA Clearance of Investigational New Drug..

Your Recent History

NASDAQ
PCVX
Vaxcyte
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved